Company
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Regeneron Pharmaceuticals Inc is a leading biotechnology company that invents, develops, and commercializes life-transforming medicines for people with serious diseases. Founded and led for over 35 years by physician-scientists, Regeneron's unique ability to repeatedly and consistently translate science into medicine has led to numerous FDA-approved treatments and product candidates in development, almost all of which were homegrown in Regeneron's laboratories.
37 stories · page 1 of 2
Archive
Introducing the First AI Model That Translates 100 Languages Without Relying on English
•Facebook AI is introducing M2M-100, the first multilingual machine translation (MMT) model that can translate between any pair of 100 languages without relying on English data. It’s open sourced here.
CytoDyn appoints pharma industry veteran Dr Seenu Srinivasan as its executive director of CMC Regulatory Affairs
Dr Srinivasan is a former director of CMC Regulatory Affairs for Regeneron Pharmaceuticals and has 30 years of broad regulatory and drug development experience
Regeneron antibody cocktail cuts risk of death for patients in hospital, study finds
Researchers at the University of Oxford analysed the drug as part of the wider RECOVERY trial, which has been investigating potential treatment for COVID-19
Tiziana Life Sciences: Wall Street's HC Wainwright repeats 'buy' call and US$11 price target after Covid trial completion and hiring of heavy-hitting chief medical officer
HC Wainwright's analyst Raghuram Selvaraju provided his assessment of recent developments
Investments and investor services
Regeneron Pharmaceuticals tops 3Q earnings and revenue estimates; shares edge higher
The drugmaker is trying to grow and diversity its business
Clearside Biomedical shares slide after failed Phase 3 trial, but a plan B is in the works
Its Phase 3 clinical trial of eye disease drug Xipere failed to meet its primary endpoint
Shares in bluebird bio soar after it strikes partnership with Regeneron to work on immune cell therapies
Investors gave a thumbs up to the deal, which allows the Massachusetts-based biotech to split R&D costs with Regeneron on its lead cancer products
Investments and investor services
Wall Street ignores Trump’s call for lower drug prices, Dow industrials extend rally to seventh session
The tech-heavy Nasdaq bucked the trend and fell, helped lower by Symantec's disastrous showing
Regeneron higher after key drugs help deliver market-beating fourth quarter
The company’s key drugs – Praluent and Dupixent, and sales of Eyelea in the US – helped to lift the numbers for the quarter